144 related articles for article (PubMed ID: 22571484)
1. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition.
Niwa T; Yamazaki H
Curr Drug Metab; 2012 Oct; 13(8):1145-59. PubMed ID: 22571484
[TBL] [Abstract][Full Text] [Related]
2. Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jul; 12(6):549-69. PubMed ID: 21476971
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
4. Substrate Specificity of Human Cytochrome P450 (CYP) 2C Subfamily and Effect of Azole Antifungal Agents on CYP2C8.
Niwa T; Imagawa Y
J Pharm Pharm Sci; 2016; 19(4):423-429. PubMed ID: 28057172
[TBL] [Abstract][Full Text] [Related]
5. Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants.
Rokitta D; Fuhr U
Curr Drug Metab; 2010 Feb; 11(2):153-61. PubMed ID: 20359285
[TBL] [Abstract][Full Text] [Related]
6. Cloning of a cDNA encoding a novel marmoset CYP2C enzyme, expression in yeast cells and characterization of its enzymatic functions.
Narimatsu S; Torigoe F; Tsuneto Y; Saito K; Hanioka N; Masuda K; Katsu T; Yamamoto S; Yamano S; Baba T; Miyata A
Biochem Pharmacol; 2006 Dec; 72(12):1738-48. PubMed ID: 17010942
[TBL] [Abstract][Full Text] [Related]
7. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts.
Pan Y; Tiong KH; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Ong CE
J Ethnopharmacol; 2012 Sep; 143(2):586-91. PubMed ID: 22885070
[TBL] [Abstract][Full Text] [Related]
9. Differential expression and function of CYP2C isoforms in human intestine and liver.
Läpple F; von Richter O; Fromm MF; Richter T; Thon KP; Wisser H; Griese EU; Eichelbaum M; Kivistö KT
Pharmacogenetics; 2003 Sep; 13(9):565-75. PubMed ID: 12972955
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics investigations of regioselectivity of anionic/aromatic substrates by a family of enzymes: a case study of diclofenac binding in CYP2C isoforms.
Cui YL; Xu F; Wu R
Phys Chem Chem Phys; 2016 Jun; 18(26):17428-39. PubMed ID: 27302079
[TBL] [Abstract][Full Text] [Related]
11. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
12. Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template.
Lewis DF; Dickins M; Lake BG; Goldfarb PS
Drug Metabol Drug Interact; 2003; 19(4):257-85. PubMed ID: 14768974
[TBL] [Abstract][Full Text] [Related]
13. Heterotropic cooperativity in oxidation mediated by cytochrome p450.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2008 Jun; 9(5):453-62. PubMed ID: 18537580
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase.
Hosaka S; Murayama N; Satsukawa M; Uehara S; Shimizu M; Iwasaki K; Iwano S; Uno Y; Yamazaki H
Drug Metab Dispos; 2015 Jul; 43(7):1119-22. PubMed ID: 25948712
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.
Wang X; Yu T; Liao X; Yang C; Han C; Zhu G; Huang K; Yu L; Qin W; Su H; Liu X; Peng T
Cancer Med; 2018 Apr; 7(4):966-980. PubMed ID: 29479826
[TBL] [Abstract][Full Text] [Related]
17. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
[TBL] [Abstract][Full Text] [Related]
18. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
[TBL] [Abstract][Full Text] [Related]
19. Amino acid residues affecting the activities of human cytochrome P450 2C9 and 2C19.
Niwa T; Kageyama A; Kishimoto K; Yabusaki Y; Ishibashi F; Katagiri M
Drug Metab Dispos; 2002 Aug; 30(8):931-6. PubMed ID: 12124312
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of cytochrome P450 enzymes from the CYP2C subfamily in the human brain.
Booth Depaz IM; Toselli F; Wilce PA; Gillam EM
Drug Metab Dispos; 2015 Mar; 43(3):353-7. PubMed ID: 25504503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
